RxDoctor Payments Data

Lisa Galeski

Psychiatric/Mental Health · Springfield, MONPI 1548894611

Payments from drug & device makers

$992in general payments, 2019–2025

Across 52 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$524
  • Axsome Therapeutics, Inc.$96
  • Teva Pharmaceuticals USA, Inc.$77
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66
  • Otsuka America Pharmaceutical, Inc.$61
  • Lundbeck LLC$54
  • plus $115 from 3 others

What the payments were for

  • Food & beverage$992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$992 in reported general payments places this provider in the 50th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$9,316
Medicare patients
40
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate45$126,377
Abilify MaintenaAripiprazole33$93,761
VraylarCariprazine Hcl55$81,592
RexultiBrexpiprazole28$52,003
PerserisRisperidone13$31,780
TrintellixVortioxetine Hydrobromide53$28,114
Lurasidone Hcl34$17,584
Chlorpromazine Hcl40$8,315
Bupropion XlBupropion Hcl110$7,494
Hydroxyzine Hcl254$6,243
Atomoxetine Hcl47$4,984
Aripiprazole164$4,208
Quetiapine Fumarate221$3,780
Duloxetine Hcl155$3,453
Buspirone Hcl223$2,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$61$145,76461 claims
AbbVieVraylar$524$81,59255 claims
Indivior Inc.Perseris$52$31,78013 claims
Teva Pharmaceuticals USA, Inc.Loxapine$77$65332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →